OR WAIT 15 SECS
October 08, 2015.
The obesity treatment market could be transformed by a "highly innovative and diverse pipeline that includes 248 products in active development", according to GBI Research. Currently, factors such as the sparse, long-term treatment options for obesity and the modest efficacy of anti-obesity drugs in sustaining body weight reduction are driving efforts to address the unmet need for effective therapeutics with favorable safety profiles, GBI analyst Angel Wong explained. The GBI report states that the obesity pipeline contains a high level of diversity in both molecule types and molecular targets, with 39% of the pipeline products with disclosed molecular targets classified as first-in-class. Small molecules account for 66% of the overall pipeline and are the dominant molecule type in all stages of development. Biologic therapeutics, consisting largely of peptides, proteins, antibodies and vaccines, also feature prominently.